Login to Your Account



Chinese biopharmas invest in the future of home-grown biologics, biosimilars

By Cornelia Zou
Staff Writer

Wednesday, June 4, 2014

HONG KONG – Chinese biopharmaceutical companies are upping the ante in the development of biological drugs and biosimilars of existing best sellers, many of them looking to capitalize on the huge domestic market.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription